MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-08-2023
Horizon Therapeutics Public Limited Company ROA Ratio 2011-2026 | HZNP
Annual ROA Ratio Horizon Therapeutics Public Limited Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.72 | 6.16 | 6.42 | 12.92 | -0.97 | -8.33 | -3.86 | 1.29 | -23.66 | -58.99 | -45.25 | -112.03 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.92 | -112.03 | -18.38 |
Quarterly ROA Ratio Horizon Therapeutics Public Limited Company
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.98 | 5.95 | 6.18 | 9.97 | 9.92 | 11.85 | 4.15 | 7.29 | 8.31 | 5.07 | 6.42 | 16.64 | 12.23 | 13.43 | 12.92 | 2.13 | 2.57 | 2.06 | -0.97 | -4.46 | -6.82 | -11.18 | -9.55 | -11.68 | -10.31 | -4.98 | -3.89 | -0.06 | 0.18 | 0.87 | 1.29 | -2.33 | -2.26 | -5.74 | -23.28 | -61.18 | -63.54 | -68.39 | -58.99 | -30.8 | -37.36 | -41.8 | -45.26 | -108.62 | -116.93 | -116.7 | -112.06 | -17.05 | -11.51 | -7.59 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.64 | -116.93 | -17.02 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 3.56 | - | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
-27.92 | $ 3.13 | - | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-101.11 | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-37.22 | $ 4.22 | - | $ 105 M | Schweiz |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.79 | 0.01 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
argenx SE
ARGX
|
-14.32 | $ 703.3 | - | $ 25 B |  Niderland |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 231.03 | 2.23 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.61 | - | $ 8.69 B |  Australia |
 |
Atea Pharmaceuticals
AVIR
|
-50.23 | $ 6.05 | - | $ 493 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 6.63 | - | $ 182 M |  Israel |
 |
BioCardia
BCDA
|
-387.38 | $ 1.27 | - | $ 26.9 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-144.48 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
5.95 | $ 11.58 | - | $ 1.03 B | USA |
 |
Cerus Corporation
CERS
|
-7.04 | $ 1.8 | 6.51 % | $ 343 M | USA |
 |
Anika Therapeutics
ANIK
|
-30.55 | $ 14.36 | - | $ 210 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 90.54 | - | $ 27.2 B | Germany |
 |
Aptose Biosciences
APTO
|
-251.11 | - | -45.71 % | $ 1.2 M | Canada |
 |
Burford Capital Limited
BUR
|
5.51 | $ 8.05 | - | $ 1.34 B | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-50.64 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
CNS Pharmaceuticals
CNSP
|
-170.76 | $ 2.45 | 0.41 % | $ 936 K | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.64 | - | $ 16.6 M | USA |
 |
Cardiff Oncology
CRDF
|
-74.09 | $ 1.9 | - | $ 127 M | USA |
 |
CorMedix
CRMD
|
19.74 | $ 6.54 | - | $ 471 K | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.51 | - | $ 385 M | Britain |